ArticleAntimicrobial agents and chemotherapy2006
Combinations of R207910 with drugs used to treat multidrug-resistant tuberculosis have the potential to shorten treatment duration.
Article in Antimicrobial agents and chemotherapy, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
50 citing papers in PubMed, 145 citations in OpenAlex.
- Impact of Rifabutin or Rifampin on Bedaquiline Safety, Tolerability, and Pharmacokinetics Assessed in a Randomized Clinical Trial with Healthy Adult Volunteers.Antimicrobial agents and chemotherapy · 2018Trial
- Early bactericidal activity and pharmacokinetics of the diarylquinoline TMC207 in treatment of pulmonary tuberculosis.Antimicrobial agents and chemotherapy · 2008Trial
- Efficacies of Sequenced Monotherapies of Mycobacterium avium Lung Infection in Mouse.The Journal of infectious diseases · 2026Article
- Assessing the efficacy of combined treatment using bedaquiline against clinical isolates of multidrug-resistant Mycobacterium tuberculosis in vitro and the macrophage model.BMC microbiology · 2026Article
- Efficacies of sequenced monotherapies ofbioRxiv : the preprint server for biology · 2025Article
- The efficacy of a regimen comprising clarithromycin, clofazimine, and bedaquiline in a mouse model of chronicAntimicrobial agents and chemotherapy · 2025Article
- Regimen comprising clarithromycin, clofazimine and bedaquiline is more efficacious than monotherapy in a mouse model of chronicbioRxiv : the preprint server for biology · 2024Article
- Contribution of direct InhA inhibitors to novel drug regimens in a mouse model of tuberculosis.Antimicrobial agents and chemotherapy · 2024Article
- Investigating the treatment shortening potential of a combination of bedaquiline, delamanid and moxifloxacin with and without sutezolid, in a murine tuberculosis model with confirmed drug exposures.The Journal of antimicrobial chemotherapy · 2024Article
- Efficacy of Omadacycline-Containing Regimen in a Mouse Model of Pulmonary Mycobacteroides abscessus Disease.mSphere · 2023Article
- Population pharmacokinetics and model-based dosing evaluation of bedaquiline in multidrug-resistant tuberculosis patients.Frontiers in pharmacology · 2023Article
- Recent developments in the identification and biosynthesis of antitumor drugs derived from microorganisms.Engineering microbiology · 2022Review
- Novel Type of Tetranitrosyl Iron Salt: Synthesis, Structure and Antibacterial Activity of Complex [FeL'Molecules (Basel, Switzerland) · 2022Article
- The pipeline of new molecules and regimens against drug-resistant tuberculosis.Journal of clinical tuberculosis and other mycobacterial diseases · 2021Review
- Comparative Efficacy of the Novel Diarylquinoline TBAJ-876 and Bedaquiline against a ResistantAntimicrobial agents and chemotherapy · 2021Article
- Comparative Efficacy of the Novel Diarylquinoline TBAJ-587 and Bedaquiline against a ResistantAntimicrobial agents and chemotherapy · 2021Article
- Bioenergetics of Mycobacterium: An Emerging Landscape for Drug Discovery.Pathogens (Basel, Switzerland) · 2018Review
- Sterilizing Activity of Fully Oral Intermittent Regimens against Mycobacterium Ulcerans Infection in Mice.PLoS neglected tropical diseases · 2016Article
- Bedaquiline for the treatment of multidrug-resistant tuberculosis: great promise or disappointment?Therapeutic advances in chronic disease · 2015Review
- Contribution of the nitroimidazoles PA-824 and TBA-354 to the activity of novel regimens in murine models of tuberculosis.Antimicrobial agents and chemotherapy · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The objective of the present study was to identify the optimal R207910-containing regimen to administer to patients who cannot receive rifampin (RIF) and isoniazid (INH) because of multidrug-resistant tuberculosis (MDR-TB), concomitant use of antiretroviral drugs, or toxicity. Mice were infected intravenously with 5 x 10(6) CFU of the H37Rv strain and treated five times per week with R207910 alone or various combinations of R207910 with the second-line drugs amikacin (AMK), pyrazinamide (PZA), moxifloxacin (MXF), and ethionamide (ETH). All R207910-containing regimens were significantly more active than the non-R207910-containing regimens after 1 month of therapy. When given for 2 months, R207910 alone was more active than the WHO standard first-line regimen RIF-INH-PZA. When R207910 was combined with second-line drugs, the combinations were more active than the currently recommended regimen of MDR-TB AMK-ETH-MXF-PZA, and culture negativity of both the lungs and spleen was reached after 2 months of treatment in almost every case.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.